Seoul, South Korea – June 8, 2026 – Global investment firm Carlyle (NASDAQ: CG) today announced that it has signed a definitive agreement to acquire up to 100% of Chung Ho Group (“Chung Ho”), a leading Korean home and healthcare appliance (“HHA”) rental platform. Equity for the investment will come from investment funds affiliated with Carlyle Asia Partners (“CAP”), its Asia buyout platform.

This proprietary, succession-driven transaction is between Carlyle and the members of the Joung family, the company’s current shareholders. Terms of the transaction are not disclosed.

Founded in 1993 by the late Chairman Dr. H.D. Joung, Chung Ho has evolved from a water purifier manufacturer into a vertically integrated Korean HHA rental platform, with operations spanning finished-product rental, filter and component manufacturing, and in-house installation and after-sales services. The company serves a large, recurring customer base through a nationwide service network and has built a strong reputation for innovation in premium water purifiers, air purifiers, bidets, mattresses and other HHA products.

Carlyle believes Chung Ho is well-positioned to benefit from long-term consumer demand for health and wellness-related home appliances and the continued adoption of subscription-based products and services. Carlyle intends to support the company by investing further in its brand as well as product innovation capabilities to continue providing customers with reliable, high-quality services.

John Kim, Chairman of Carlyle Korea for CAP, said: “We believe Chung Ho is one of the leading Korean water purifier and home appliance companies, underpinned by strong brand equity and product capabilities. We are excited about the opportunity to partner with Chung Ho and to leverage Carlyle’s experience and global network to further strengthen the company’s market position and support its next phase of growth.”

Icksoo Jung, Head of Carlyle Korea for CAP, said: “This succession‑driven investment underscores Carlyle’s ability to provide solutions in complex ownership and succession transitions for founder‑led businesses in Korea. Carlyle has a deep understanding and strong expertise in navigating such transitions, which we believe will become increasingly important in the Korean market.”

Dr. Kyung Eun Lee, Chairwoman of Chung Ho Group, said: “For more than three decades, Chung Ho has focused on delivering reliable, high‑quality products and services to Korean consumers and has pioneered the premium water purifier and home appliance market. We believe this partnership with Carlyle will help the company build on Chairman H.D. Joung’s legacy, continue to innovate, and create greater value for Chung Ho’s customers and employees.”

The transaction is expected to close in the third quarter of 2026, subject to customary regulatory approvals and closing conditions.

Carlyle is a leading global investment firm that has a long-standing presence in Korea, having invested more than US$4 billion in the market over the past two decades. Notable investments in Korea include ADT Caps, KB Financial Group, Kakao Mobility, A Twosome Place, Hyundai Glovis and KFC Korea.

About Carlyle

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Carlyle AlpInvest. With $475 billion of assets under management as of March 31, 2026, Carlyle’s purpose is to connect people, ideas, and capital to fuel growth for companies and performance for investors. Carlyle employs more than 2,500 people in 28 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.

Media Contacts

Carlyle
Lonna Leong
+852 9023 1157
lonna.leong@carlyle.com​

The SIGNATURE
Jason Sohn
+82 10 9622 5915
jason.sohn@thesignature.co.kr

CapMan Growth exits Silmäasema – Terveystalo acquires all shares in the company

CapMan Growth Equity II fund, together with the other owners of Silmäasema Oy, has signed an agreement to sell all shares in the company to Terveystalo Plc and its subsidiary, Terveystalo Healthcare Oy. The transaction strengthens the position of the combined Terveystalo and Silmäasema entity in the growing eye health market and enables the provision of even better services and care for customers.

Silmäasema is Finland’s leading vision and eye health company in both private eye health services and optical retail. CapMan Growth invested in Silmäasema through the Growth Equity II fund in 2023 as part of an approximately EUR 40 million investment round. In connection with the same transaction, CapMan Growth exited Coronaria Oy, which has served as Silmäasema’s largest shareholder and will become Terveystalo’s largest shareholder upon completion of the transaction. Antti Kummu, Managing Partner at CapMan Growth, has served as Chair of Silmäasema’s Board of Directors since 2019.

Silmäasema’s revenue has grown steadily and outpaced the market at an average annual rate of 16% during CapMan Growth’s ownership period in 2020–2025. The company’s revenue has more than doubled to EUR 267 million, while EBITDA (IFRS) has quadrupled to over EUR 55 million (2025). During this time, Silmäasema has also become the market leader in its sector in Finland. An important driver of Silmäasema’s strong growth and high profitability has been its unique integrated operating model, which covers the full range of eye health services.

“I am very grateful and proud that we have been part of Silmäasema’s impressive development over several years. I would like to warmly thank Teppo Lindén, Ulla Näpänkangas, Jari-Pekka Kelhä, as well as Silmäasema’s wider management team and all employees for their excellent work in driving the company’s growth and development. Silmäasema has played an important role in Finnish eye health, and the transaction with Terveystalo opens up new opportunities for the company and creates a strong foundation for future growth,” comments Antti Kummu.

Completion of the transaction is subject to approval by the Finnish Competition and Consumer Authority and a resolution by Terveystalo’s Extraordinary General Meeting authorising Terveystalo’s Board of Directors to issue the consideration shares.

The exit is CapMan Growth’s tenth to date and the second for the Growth Equity II fund.

For more information:

Antti Kummu, Managing Partner, CapMan Growth, +358 50 432 4486

About CapMan

CapMan is a leading Nordic private asset expert with an active approach to value creation and 7.2 billion euros in assets under management. As one of the private equity pioneers in the Nordics we have developed hundreds of companies and assets creating significant value for over three decades. Our objective is to provide attractive returns and innovative solutions to investors by enabling change across our portfolio companies. An example of this is greenhouse gas reduction targets that we have set under the Science Based Targets initiative in line with the 1.5°C scenario and our commitment to net-zero GHG emissions by 2040. We have a broad presence in the unlisted market through our local and specialised teams. Our investment strategies cover real estate and infrastructure assets, real asset debt, natural capital and minority and majority investments in portfolio companies. We also provide wealth management solutions. Altogether, CapMan employs around 200 professionals in Helsinki, Jyväskylä, Stockholm, Copenhagen, Oslo, London, Luxembourg, and Düsseldorf. We are listed on Nasdaq Helsinki since 2001. www.capman.com.

About Silmäasema

Silmäasema is the largest eye health and optical retail operator in Finland. We see the whole picture, from meeting and treating our patients to Finnish eye health as a whole. Silmäasema’s more than 1,700 vision and eye health professionals treat close to one million customers every year. Silmäasema has 155 optical stores and ophthalmologist centres, 20 private eye hospitals and 5 units providing public eye health services across Finland. Silmäasema’s turnover in 2025 was 267 million euros. In Estonia, Silmäasema has 10 optical retail locations under the Eagle Vision brand.

Groupe Bruxelles Lambert (“GBL”) has successfully completed the acquisition of a 45% co-control stake in Rayner (“Rayner”), a leading manufacturer of intraocular lenses and related products. GBL will invest €0.5bn of equity alongside incumbent shareholders CVC and the Rayner management team. Through this investment, announced on February 9, 2026, GBL will have co-control rights alongside CVC.

Rayner produces a full range of ophthalmic solutions (including lenses, surgical instruments, machines, eye drops), that help restore sight in patients undergoing cataract and refractive surgeries. Headquartered in the UK, Rayner markets its products through direct sales teams and distributors. The company has a global presence, with sales in over 80 countries across 6 continents, and direct sales teams in 16 countries.

This transaction aligns with GBL’s ambition (i) to invest in assets in which the group has control or co-control and (ii) to increase the share of direct private assets within its portfolio, as communicated at the group’s Mid-term Strategic Update in November 2024. This investment, the first of three1 announced this year, marks another in healthcare, which the group has identified as one of five priority sectors2. The healthcare sector, supported by favorable long-term demographic trends and growth perspectives, presents attractive investment opportunities. In addition, fragmentation across geographies and activities lends itself to ample value-creative M&A.

For additional information:

Xavier Likin Chief Financial Officer

Tel: +32 2 289 17 72 xlikin@gbl.com

For CVC: Nick Board Director, Communications

Tel: +44 20 7420 4200

nboard@cvc.com

For Rayner: marketingteam@rayner.com

About Rayner

Alison Donohoe Head of Investor Relations Tel: +32 2 289 17 64 adonohoe@gbl.com Since the implantation of the first Rayner intraocular lens by Sir Harold Ridley in 1949, Rayner has continuously pioneered intraocular lens (IOL) design with a goal to improve vision and restore sight worldwide. Today, Rayner continues to deliver innovative and clinically superior ophthalmic products that respond to the expectations of our global customers to improve the sight and quality of life of their patients. Headquartered in Worthing, UK, Rayner markets its IOL, OVD and dry eye portfolio, worldwide in over 80 countries. For more information: www.rayner.com

About CVC

CVC is a leading global private markets manager with a network of 29 office locations throughout EMEA, the Americas, and Asia, with approximately €209bn of assets under management. CVC has seven complementary strategies across private equity, secondaries, credit and infrastructure, for which CVC funds have secured commitments of over €257bn from some of the world’s leading pension funds and other institutional investors. Funds managed or advised by CVC’s private equity strategy are invested in approximately 150+ companies worldwide, which have combined annual sales of over €240bn and employ nearly 660,000 people. For further information about CVC please visit: www.cvc.com. Follow us on LinkedIn.

About Groupe Bruxelles Lambert

GBL is an established investment holding company, with over seventy years of stock exchange listing and a net asset value of €13.3bn at the end of March 2026. As a leading and active investor in Europe, GBL focuses on long-term value creation with the support of a stable family shareholder base. GBL is focused on delivering meaningful growth by providing attractive returns to its shareholders through a combination of growth in its net asset value per share, a sustainable dividend and share buybacks.

GBL is listed on Euronext Brussels (Ticker: GBLB BB; ISIN code: BE0003797140) and is included in the BEL20 index. Press release – May 28, 2026 // Page 2 / 2 // For

Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt

Combined with company’s current total cash of $1.3 billion, this transaction positions Apogee to achieve a self-sustainable financial profile through commercialization of zumilokibart without need for future equity financing

Apogee to host webcast with the APEX Phase 2 Part B results today at 8:00 a.m. Eastern Time

San Francisco and Boston, May 27, 2026 — Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced that it has entered into a strategic financing collaboration with funds managed by Blackstone Life Sciences (“Blackstone”) for up to $1.3 billion in flexible, non-dilutive total capital to support the continued development and potential commercialization of zumilokibart.

“Our partnership with Blackstone Life Sciences represents a major milestone in the advancement of zumilokibart as the next meaningful first line therapy for moderate-to-severe atopic dermatitis,” said Michael Henderson, M.D., Chief Executive Officer of Apogee Therapeutics. “This collaboration provides non-dilutive flexible funding at an attractive cost of capital for the late-stage development of zumilokibart and establishes a path to commercialization and profitability for Apogee. As supported by our Apex Part B data announced today, we believe zumilokibart has the potential to be a transformative therapy for patients with differentiated efficacy and dosing in atopic dermatitis and other large I&I indications.”

“We are excited to support Apogee’s advancement of zumilokibart through Phase 3 development and potential commercialization,” said Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences. “Our collaboration with Apogee is a great example of our strategy to provide leading biotechnology companies with non-dilutive financing at scale and the resources and flexibility to further scientific innovation and invest in the advancement of their pipelines.”

Added Kiran Reddy, M.D., Senior Managing Director, Blackstone Life Sciences, “This is the largest royalty financing for a pre-Phase 3 program to date. It reflects our conviction that zumilokibart has the potential to become a highly differentiated, multi-indication product that will have a major impact on patients’ quality of life.”

Transaction Overview
The collaboration agreement provides for up to $1.3 billion in flexible, non-dilutive total capital, including up to $800 million of synthetic royalty and up to $500 million of senior debt available at the mutual consent of Apogee and Blackstone.

Synthetic royalty: Blackstone will provide up to $800 million of synthetic royalty funding in exchange for low-to-mid single digit tiered royalties for a term of 15 years on worldwide annual sales of zumilokibart. The royalties decrease based on sales with no royalties on global annual sales in excess of $8 billion.

• The first $400 million in preapproval funding is divided into 3 tranches, including $100 million at signing, $100 million upon completion of zumilokibart Phase 3 enrollment, and $200 million upon positive Phase 3 data. Upon FDA approval of zumilokibart, up to $400 million in additional funding is available, $150 million of which is at Apogee’s option

• The funding agreement includes specific provisions on a change of control, with the option to buy back a significant portion of the royalty.

• Senior debt: Up to $500 million of senior corporate debt is available at mutual consent of Apogee and Blackstone

Additional details regarding the funding agreement can be found in the Current Report on Form 8-K filed by the company today with the U.S. Securities and Exchange Commission.

Cash runway update
As a result of entering into this funding agreement with Blackstone, the company is removing its cash runway end date guidance.

Webcast Details
Apogee Therapeutics will hold a live webcast to discuss the Blackstone transaction and the results of the APEX Phase 2 Part B trial today at 8:00 a.m. ET. The live webcast can be accessed via this link or the Investors section on the company’s website at https://investors.apogeetherapeutics.com/news-events/events. A replay of the webcast will be available following the call.

Advisors
Goldman Sachs served as exclusive financial advisor and Latham & Watkins LLP as legal counsel to Apogee Therapeutics. Ropes & Gray LLP served as legal counsel to Blackstone Life Sciences.

About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, eosinophilic esophagitis (EoE), Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets, as well as asthma and EoE. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.

About Blackstone Life Sciences
Blackstone Life Sciences (BXLS) is a leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, BXLS helps bring to market promising new medicines and medical technologies that improve patients’ lives and currently has $17 billion in assets under management.

Forward Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements regarding Apogee’s expectations regarding: Apogee’s plans for its current and future product candidates, programs, and clinical trials, including the Phase 3 development and potential commercialization of zumilokibart and expansion of zumilokibart into additional indications; the potential clinical benefit, dosing regimen, safety and efficacy profiles and treatment outcomes of zumilokibart, including its potential to be a best-in-class therapy, be the next meaningful first line therapy for AD, overcome limitations of existing therapies, and be the new standard of care in AD; the potential for Apogee product candidates and programs to overcome limitations of existing therapies; the potential of zumilokibart to become a differentiated, multi-indication product; its planned business strategies; the financial resources available to Apogee, including the availability of capital from the synthetic royalty and potential debt arrangement and whether Apogee achieves the milestones associated with certain payments thereunder and whether Apogee elects to receive optional funding under the arrangement, if available; its expectations regarding the time period over which Apogee’s capital resources will be sufficient to fund its anticipated operations, including its self-sustainable financial profile through commercialization of zumilokibart without the need for future equity financing; its potential profitability; and estimates of market size. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Apogee believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to Apogee on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Apogee’s filings with the U.S. Securities and Exchange Commission (the SEC)), many of which are beyond Apogee’s control and subject to change. Actual results could be materially different. Risks and uncertainties include: global macroeconomic conditions and related volatility, expectations regarding the initiation, progress, and expected results of Apogee’s preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion and outcome of Apogee’s clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the applicability of clinical study results to actual outcomes; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in Apogee’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 2, 2026, and subsequent disclosure documents Apogee may file with the SEC. Apogee claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Apogee expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

Apogee Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
Noel.Kurdi@apogeetherapeutics.com

Apogee Media Contact:
Dan Budwick
1AB Media
dan@1abmedia.com

Blackstone Life Sciences Media Contact:
David Vitek
(212) 583-5291
David.Vitek@Blackstone.com